RxDoctor Payments Data

Louis Verstringhe, MD

Ophthalmology · Shenandoah, TXNPI 1043429046

Payments from drug & device makers

$4,494in general payments, 2019–2025

Across 170 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$652
  • Sun Pharmaceutical Industries Inc.$529
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$406
  • Oyster Point Pharma, Inc.$326
  • Novartis$236
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,494 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$497,765
Medicare patients
1,459
Services billed
4,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost150$86,077
RestasisCyclosporine81$79,905
XiidraLifitegrast30$29,500
RhopressaNetarsudil Mesylate46$25,119
TyrvayaVarenicline Tartrate24$20,027
RocklatanNetarsudil Mesylat/Latanoprost36$19,278
Cyclosporine39$18,324
Latanoprost1,149$13,923
VyzultaLatanoprostene Bunod27$11,666
CequaCyclosporine17$11,551
CombiganBrimonidine Tartrate/Timolol23$10,559
Travoprost37$9,136
Alphagan PBrimonidine Tartrate30$7,755
Dorzolamide-TimololDorzolamide/Timolol/Pf39$6,660
SimbrinzaBrinzolamide/Brimonidine Tart27$6,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,253$184,297284 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$130$44,39682 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$170$41,16657 claims
Oyster Point Pharma, Inc.Tyrvaya$326$20,02724 claims
Sun Pharmaceutical Industries Inc.Cequa$529$11,55117 claims
AlconSimbrinza$652$6,64327 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$406$5,11247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →